Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma
Siguo Hao(XinHua Hospital), Hong Ma(Fujian Medical University), Chongyun Xing(Zhejiang Chinese Medical University), Zonghai Li(Guizhou Normal University), Songfu Jiang(Wenzhou Medical University), Jun Xiao(Regend Therapeutics (China)), Linjun Chen(XinHua Hospital), Jian‐Bo Wan(University of Macau), Lihui Dai(Wenzhou Medical University), Mingxia He(Wenzhou Medical University), Rong Tao(Shanghai Jiao Tong University), Xin Huang(Capital Medical University), Wei Wang(Central South University), Wenhao Zhang(Northeast Forestry University), Shasha Wang(Chinese PLA General Hospital), Kang Yu(Wenzhou Medical University), Min Yang(First Affiliated Hospital Zhejiang University), Jie Jin(Beijing Institute of Technology), Haitao Meng(First Affiliated Hospital Zhejiang University), Daijing Yuan(Regend Therapeutics (China))
Cited by 36
Related Papers
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines
|Nature Communications|2020|613
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238